Madrigal Pharmaceuticals, Inc. Common Stock
MDGLStock
$545.53+76.85%52W
Market Cap$12.58B
P/E—
Div yield—
Beta-1.06
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.40%
Price vs S&P 500 (4W)9.19%
VGM Score57.06
Market Capitalization$12.58B
Earnings Surprise History
Q1 26-3.25est. -4.11
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDGLMadrigal Pharmaceuticals, Inc. Common Stock | F | A | B | $545.53 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor beta agonist designed to address the underlying causes of MASH and prevent progression to cirrhosis and liver failure.